Ranibizumab for neovascular age-related macular degeneration.
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY.
N Engl J Med. 2006 Oct 5;355(14):1419-31. Full text
Main finding: Ranibizumab prevented vision loss and improved mean visual acuity in patients with minimally classic or occult CNV secondary to AMD
Purpose: To evaluate ranibizumab for the treatment of minimally classic or occult with no classic choroidal neovascularization associated with age-related macular degeneration.
Study type: Randomized clinical trial
Condition: CNV secondary to AMD
Participants: ≥50yo, minimally classic or occult CNV, BCVA 20/40-20/320
n=716
Intervention:
Group 1: Intravitreal Ranibizumab 0.3mg
Group 2: Intravitreal Ranibizumab 0.5mg
Group 3: Sham
Outcomes
Group
Sham
RAN 0.3mg
RAN 0.5mg
Lost < 15 letters from baseline
12 months
62.2%
94.5%
94.6%
24 months
52.9%
92.0%
90.0%
Gained ≥ 15 letters
5.0%
24.8%
33.8%
VA change (letters)
12 months
-10.4
+6.5
+7.2
24 months
Share This Article :
Please provide feedback on content published. Thank you.
Source Archive